Key Highlights
- OrsoBio secures $67M Series B financing, led by Ascenta Capital and Woodline Partners.
- Proceeds will accelerate development of OrsoBio’s mitochondrial protonophore portfolio for obesity treatment.
- Dr. Evan Rachlin joins OrsoBio’s Board of Directors as part of the new investment.
Source: Business Wire
Notable Quotes
- “We believe that the future of obesity treatment will include GLP-1 RA-based combinations; this financing will enable us to build the scientific and clinical foundations to support our protonophores as components of these regimens.” — Mani Subramanian, MD, PhD, CEO and Founder at OrsoBio
- “OrsoBio’s novel mechanisms hold promise to enhance weight loss, improve metabolic function, and preserve lean muscle mass.” — Evan Rachlin, MD, Co-Founder and Managing Partner at Ascenta Capital
SoHC's Take
OrsoBio’s focus on mitochondrial protonophores represents a significant advancement in the treatment of obesity, especially when combined with GLP-1 receptor agonists. This new approach could enhance patient outcomes by addressing metabolic inefficiencies and preserving lean muscle mass, a key challenge in obesity treatments today. With the backing of renowned investors and a robust clinical pipeline, OrsoBio is well-positioned to lead innovation in metabolic disorder therapies.
